HSA has granted Flowflex ART full-fledged approval
Health Sciences Authority (HSA) has granted the Flowflex ART Pre-Market Approval, indicating full-fledged approval for the product. This approval encompasses both Professional Use and Self Testing, ensuring the continued availability of Flowflex even after the expiration of the Pandemic Special Access Route (PSAR) on 30th June 2023.
With this significant milestone, Flowflex users can have complete confidence in the product's adherence to the rigorous standards set by the HSA in terms of safety, quality, and efficacy.
By obtaining HSA's approval for both Professional Use and Self Testing, we are committed to providing a comprehensive and reliable testing solution that caters to diverse needs and situations. This endorsement further validates our dedication to upholding the highest standards in healthcare.
As a Flowflex user, you can rest assured that our product has undergone rigorous evaluation and meets all the necessary requirements set forth by the HSA.
Thank you for your continued trust in Flowflex. We will continue to prioritize excellence and deliver solutions to support your testing needs.